Oculis Showcases Innovative Pipeline at Key Events
Oculis Holding AG (NASDAQ: OCS) has announced exciting updates about its promising late-stage pipeline that will be the center of attention at significant industry events including Eyecelerator and the American Academy of Ophthalmology (AAO) Annual Meeting. These events will spotlight Oculis' commitment to addressing challenging ophthalmic and neuro-ophthalmic conditions.
Presenting Innovations at Eyecelerator
At the Eyecelerator event, Oculis' CEO, Riad Sherif, MD, will deliver a presentation focused on the advancements within the company's late-stage pipeline. Key highlights will cover the promising acceleration of Privosegtor into pivotal registrational trials targeting acute optic neuritis and non-arteritic anterior ischemic optic neuropathy due to a favorable discussion with the U.S. Food and Drug Administration (FDA). This proactive approach signifies Oculis' dedication to rapid advancement in critical areas of vision health.
Upcoming Trials and Programs
Additionally, attendees can expect updates on the Phase 3 DIAMOND program involving OCS-01 eye drops, aimed at treating diabetic macular edema, with results anticipated in the second quarter of 2026. There will also be insights into the forthcoming PREDICT-1 trial, which will utilize a genotype-driven strategy to explore Licaminlimab for dry eye disease, expected to kick off in late 2025.
Engagement at AAO
In connection with the AAO proceedings, Oculis will actively support various significant gatherings including Innovate Retina and the inaugural meeting of the Society for Artificial Intelligence in Vision and Ophthalmology (SAIVO), in addition to the COPhy Satellite Symposium. During the Innovate Retina event, Dr. Arshad M. Khanani, a member of Oculis' Retina Scientific Advisory Board, will partake on a panel discussing eye drops, particularly the innovative OCS-01, and their potential role in reshaping treatment approaches for diabetic macular edema.
Understanding Privosegtor
Privosegtor is positioned to be a groundbreaking therapy in neuroprotection for conditions like acute optic neuritis. The Phase 2 ACUITY trial demonstrated commendable outcomes, showing that Privosegtor can preserve retinal anatomy and improve visual functionalities after acute episodes. Supportive findings from preclinical models indicate its efficacy in preserving retinal ganglion cell integrity and enhancing mobility, paving the way for a wave of optimism in neuro-ophthalmic treatments.
Addressing Acute Optic Neuritis
Acute optic neuritis affects numerous individuals worldwide, striking primarily between the ages of 20 to 40 and often serves as an initial indicator of multiple sclerosis. This inflammation can lead to severe visual loss, necessitating the need for effective neuroprotective treatments like Privosegtor, a candidate that hopes to fulfill these unmet treatment needs.
Focus on Non-arteritic Anterior Ischemic Optic Neuropathy
Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) remains another critical area with no approved therapies. Oculis aims to address this gap through its work with Privosegtor, focusing on preserving vision and improving patient outcomes in this population. With increasing prevalence, Oculis' involvement in researching and developing therapies for eye-related disorders is timely and necessary.
Future of Diabetic Macular Edema Treatment
Diabetic Macular Edema (DME) presents a major challenge in ophthalmology, with millions affected globally. OCS-01 aims to revolutionize treatment in this space by providing a non-invasive alternative to currently invasive methods such as injections. By enhancing accessibility and facilitating treatment in the early stages of the disease, Oculis seeks to transform the landscape of DME management.
About Oculis
As a global biopharmaceutical company, Oculis remains at the forefront of innovative solutions in neuro-ophthalmic care. With a strong pipeline featuring key candidates like Privosegtor and OCS-01, the company is dedicated to making strides in therapeutic options that tackle critical needs in eye health. Their headquarters in Switzerland is complemented by a robust presence in the U.S. and Iceland, showcasing a well-rounded commitment to advancing ophthalmic treatments.
Contact Information
If you would like to know more about Oculis, please feel free to reach out: Ms. Sylvia Cheung, CFO at sylvia.cheung@oculis.com for inquiries.
Frequently Asked Questions
What is Oculis Holding AG?
Oculis is a biopharmaceutical company focused on developing innovative treatments for ophthalmic and neuro-ophthalmic diseases.
What are the key products in Oculis' pipeline?
Key products include Privosegtor for neuroprotection and OCS-01 for diabetic macular edema.
When will Oculis present its updates?
Oculis will provide updates at Eyecelerator and AAO meetings in 2025.
How does OCS-01 work?
OCS-01 is a high-concentration dexamethasone eye drop formulation aimed at non-invasive treatment for diabetic macular edema.
What condition does Privosegtor target?
Privosegtor targets acute optic neuritis and non-arteritic anterior ischemic optic neuropathy.
